Invitation: Elekta Investor Lunch at Estro, May 9, 2011

STOCKHOLM--(BUSINESS WIRE)-- Regulatory News:

Elekta (STO:EKTAB) invites you to a lunch with members of Elekta’s executive management in conjunction with the Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO), in London, UK. The lunch is held on Monday, May 9, at 12.00 pm – 1.30 pm, in Room 21/22 located in the South Gallery at the ExCel Centre in London, UK. Elekta’s President and CEO Tomas Puusepp will be attending the lunch, as well as Johan Sedihn, Executive Vice President Elekta Oncology, and Olof Sandén, Executive Vice President Region Europe, Africa, Middle East and Latin America. We look forward to seeing you on May 9! Investors who want to attend the lunch are kindly requested to give notice by e-mail to [email protected] ([email protected]).

This information was brought to you by Cision http://www.cisionwire.com



CONTACT:

Elekta AB
Stina Thorman, Vice President Corporate Communications
Tel: +46 8 587 254 37, +46 70 778 60 10
e-mail: [email protected]
or
Elekta AB
Elisabeth Natt och Dag
Information Manager
Tel: +46 8 587 25 430, +46 733 16 16 88

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Other Health

MEDIA:

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.